TACR1 (Neurokinin-1 Receptor) Drug Discovery Landscape & Assay Solutions
- By admin
- 29 Jul 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for CINV, Pruritus, Neurogenic Inflammation, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TACR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TACR1 Premade Lentivirus Particles. Full-length ORF, HEK293T packaging. High titer, endotoxin controlled. For stable cell line construction preserving native conformation and glycosylation. | View TACR1 Products |
| Cell-Based Antigen | TACR1/HEK293 Stable Cell Line. High surface expression, sequence verified. HEK293 expressed (native glycosylation). | View TACR1 Products |
| Antigen (ECD-Fc) | TACR1 N-Terminal ECD-Fc Fusion Protein. High purity (>95%), endotoxin <1 EU/μg. Sequence verified, HEK293 expressed. | View TACR1 Products |
| Ligand Control | Substance P (TAC1) Recombinant Protein. High purity (>95%), endotoxin <1 EU/μg. Native agonist for binding/competition assays. | View TAC1 Products |
| Validator | TACR1 siRNA Set. 3 target-specific duplexes + 1 negative control. For knockdown verification and assay specificity control. | View TACR1 Products |
| Benchmark Ab | Anti-TACR1 Recombinant Antibody. Sequence verified, endotoxin controlled. Positive control for flow cytometry/IHC. | View TACR1 Products |
| Selectivity Target A (NK-2R) | TACR2 (NK-2R) Lentivirus & Cell Line. Subfamily selectivity screening (counter-target). Sequence verified by mass spec. | View TACR2 Products |
| Selectivity Target B (NK-3R) | TACR3 (NK-3R) Lentivirus & Cell Line. Subfamily selectivity screening (counter-target). Sequence verified. | View TACR3 Products |
| Related Target (5-HT3) | HTR3A (5-HT3 Receptor) Lentivirus & Cell Line. Synergistic target for CINV combination therapies. | View HTR3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity & Signaling | Lentivirus-delivered full-length TACR1 in HEK293. Native glycosylation preserved, endotoxin <1 EU/μg. Compatible with calcium flux, cAMP, and internalization assays. |
| Subfamily Selectivity (NK-1 vs NK-2/NK-3) | Parallel TACR1/2/3 cell lines with >95% purity verified ORFs. Strict sequence verification by mass spec. |
| Species Cross-Reactivity (Preclinical) | Human, cynomolgus, and mouse TACR1 lentivirus and ECD-Fc proteins available for translational pharmacology. |
| Assay Specificity Control | Validated siRNA and Substance P ligand included for positive/negative controls; benchmark antibody for assay standardization. |
| False Positives in Signaling | siRNA set included for background subtraction and target-specificity confirmation. |
Live TACR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The TACR1 antagonist landscape is evolving beyond the established antiemetic applications. First-generation small molecules (aprepitant, netupitant, rolapitant) dominate the chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) markets. However, the next wave of R&D is shifting from central nervous system (CNS) penetration toward peripheral-selective antagonism for pruritus, atopic dermatitis, gastroparesis, and chronic cough. Concurrently, emerging interest in NK-1R as a tumor microenvironment modulator is driving biologic modalities—particularly antibody-drug conjugates (ADCs), bispecific constructs, and targeted peptides—into preclinical pipelines for solid tumors such as glioblastoma and breast cancer. The demand for species-specific cell-based assays and subfamily selectivity screening has intensified, and long-acting depot formulations as well as combination strategies with 5-HT3 antagonists are gaining traction for refractory indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist (CNS-penetrant) | Merck (Aprepitant), Tesaro/GSK (Rolapitant), Menarini/Helsinn (Netupitant) | CINV, PONV | Competition binding assay (need Substance P ligand & stable cell line) |
| Peripheral-Selective Antagonist | Vyne Therapeutics (Tradipitant), Bellus Health (Camlipixant) | Pruritus, refractory chronic cough, gastroparesis | Cell-based functional assay (need native conformation lentivirus) |
| Peptide / Biologic | Various Biotech | Chronic pain, inflammation | Receptor internalization assay (need native membrane expression) |
| ADC / Targeted Biologic | Emerging Biotech / Academia | Solid tumors (GBM, breast) | Internalization assay (need full-length lentivirus-stable cells); flow cytometry binding |
| Combination Therapy | Helsinn (Netupitant/Palonosetron) | Refractory CINV | Selectivity assay (need TACR1 and HTR3A cell lines) |
| Subfamily Selective Screen | Preclinical/Biotech | Pain, inflammation | Cross-reactivity panel (need TACR1/2/3 orthologs) |
Strategic Insights: Differentiation Requirements & Assay Strategy
To develop a best-in-class TACR1 therapeutic, molecular differentiation must be validated through rigorous assay strategies:
- Affinity & Kinetics: Compete with high-affinity endogenous ligand Substance P (Kd sub-nM). Use cell-based radioligand binding or NanoBRET kinetic assays. TarMart provides lentivirus-generated stable cell lines preserving native 7TM conformation.
- Subfamily Selectivity: Avoid off-target activity at TACR2 (NK-2R) and TACR3 (NK-3R) causing smooth muscle spasm or endocrine disturbances. TarMart offers sequence-verified TACR2/TACR3 lentivirus and cell lines for rapid counter-screening panel.
- BBB Penetration: Differentiate CNS-penetrant vs. peripherally restricted drugs. Use cell permeability models (PAMPA, MDCK-MDR1) and internalization assays with calcium flux/cAMP readouts. TarMart’s lentivirus preserves native glycosylation for accurate Gq/Gs coupling.
- Species Cross-Reactivity: Preclinical safety requires cynomolgus/mouse ortholog models. TarMart provides ortholog ECD-Fc proteins and lentivirus for translational studies.